Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSP/QRH Dimer for early detection of GI malignancies
NCT03643068Phase 1Completed
- Sponsor
- University of Michigan
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of KSP-QRH-E3-IRDye800 in gastrointestinal cancer (2 cohorts), sponsored by University of Michigan. Primary endpoints: Number of subjects with abnormal lab values at 48 hours and Number of subjects with unexpected side effects at 48 hours. Started Aug 2018; status: completed.
02
Drugs
KSP-QRH-E3-IRDye800
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT03643068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643068.